Queensland Alliance for Agriculture and Food Innovation, The University of Queensland, Queensland, Australia.
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Queensland, Australia.
Int J Pharm. 2014 Apr 25;465(1-2):325-32. doi: 10.1016/j.ijpharm.2014.01.037. Epub 2014 Feb 26.
Amino functionalised mesoporous silica nanoparticles (AM-41) have been identified as a promising vaccine delivery material. The capacity of AM-41 to stabilise vaccine components at ambient temperature (23-27°C) was determined by adsorbing the model antigen ovalbumin (OVA) to AM-41 particles (OVA-41). The OVA-41 was successfully freeze-dried using the excipients 5% trehalose and 1% PEG8000. The immunological activity of OVA and the nanoparticle structure were maintained following two months storage at ambient temperature. The results of immunisation studies in mice with reconstituted OVA-41 demonstrated the induction of humoral and cell-meditated immune responses. The capacity of AM-41 particles to facilitate ambient storage of vaccine components without the loss of immunological potency will underpin the further development of this promising vaccine delivery platform.
氨基功能化介孔硅纳米颗粒（AM-41）已被确定为一种有前途的疫苗输送材料。通过将模型抗原卵清蛋白（OVA）吸附到 AM-41 颗粒上（OVA-41），确定 AM-41 在环境温度（23-27°C）下稳定疫苗成分的能力。使用赋形剂 5%海藻糖和 1%PEG8000 成功地对 OVA-41 进行了冷冻干燥。在环境温度下储存两个月后，OVA 和纳米颗粒结构的免疫活性得以维持。用重构的 OVA-41 对小鼠进行免疫研究的结果表明，诱导了体液和细胞介导的免疫反应。AM-41 颗粒能够在不丧失免疫效力的情况下促进疫苗成分在环境温度下的储存，这将为这一有前途的疫苗输送平台的进一步发展提供支持。
